Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.37 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.37 |
| ▸ | CCND1 | P24385 | 2/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 9/20 | 0.37 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16310845 | 0.87 | PAK1 (0.39) | JAK3PAK1RIPK2NOD2ACVR1 | |
| SCHEMBL15041666 | 0.77 | TNK2 (0.40) | RIPK2NOD2ACVR1CCNE1CDK2 | |
| SCHEMBL13553804 | 0.75 | CDK4 (0.46) | PAK1RIPK2NOD2ACVR1CCND1 | |
| SCHEMBL15035861 | 0.74 | PAK1 (0.41) | PAK1RIPK2NOD2ACVR1TNK2 | |
| SCHEMBL15041690 | 0.74 | PAK1 (0.52) | PAK1CCND1TNK2PAK2 | |
| SCHEMBL15036157 | 0.74 | CDK4 (0.38) | CCND1CDK2CDK6 | |
| SCHEMBL15035731 | 0.73 | RIPK2 (0.40) | PAK1RIPK2NOD2ACVR1TNK2 | |
| SCHEMBL14681988 | 0.73 | PAK1 (0.43) | PAK1CCND1TNK2PAK2 | |
| SCHEMBL16310835 | 0.73 | TNK2 (0.43) | JAK3TNK2 | |
| SCHEMBL15041454 | 0.72 | CDK4 (0.40) | PAK1CDK6TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | JAK3 460/4885PAK1 6/4885RIPK2 870/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | JAK3 1901/4885PAK1 4/4885RIPK2 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.